Journal
INTERNAL MEDICINE
Volume 59, Issue 7, Pages 977-981Publisher
JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.3928-19
Keywords
onconephrology; immune checkpoint inhibitors (CPI); pembrolizumab; immune-related adverse events (irAEs); IgA nephropathy; acute tubulointerstitial nephritis
Categories
Ask authors/readers for more resources
Immune checkpoint inhibitors (CPIs), including pembrolizumab, are becoming common oncological treatments. CPIs have been associated with a significant risk of developing immune-related adverse events (irAEs), such as nephritis and interstitial nephritis. However, the occurrence of glomerulonephritis has only rarely been reported. We herein present the case of a 75-year-old woman with non-small cell lung carcinoma (NSCLC) who developed proteinuria and microscopic hematuria during treatment with pembrolizumab. Renal biopsy revealed tubulointerstitial nephritis and IgA nephropathy. Considering that a urinalysis showed no abnormality before treatment, the condition might have been induced by pembrolizumab. hi this report, we focus on the correct diagnosis and management of renal irAEs, which remain controversial.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available